Our goal is to develop novel immunotherapies for different types of solid tumors and hematologic malignancies with a focus on Multiple Myeloma. This includes antibody-based and cellular immunotherapies such as CAR T cells and TCR-transduced T cells. We have also developed a number of techniques for the detailed immunomonitoring of clinical trials with novel immunotherapeutic agents.
3i Bridge/Pillar: Cancer
Keywords: cancer immunotherapy, tumor immunology, CAR T cells, TCR-transduced T cells, monoclonal antibodies